Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir- antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Lan, Nguyen Thi Ngoc ^a   Thu, Nguyen Thi Nguyet ^b   Barrail Tran, Aurélie ^c,j   Duc, Nguyen Hong ^a   Lan, Nguyen Ngoc ^a   Laureillard, Didier ^d   Lien, Truong Thi Xuan ^b   Borand, Laurence ^e   Quillet, Catherine ^d   Connolly, Catherine ^f   Lagarde, Dominique ^g   Pym, Alexander ^f,h   Lienhardt, Christian ⁱ   Dung, Nguyen Huy ^a   Taburet, Anne Marie ^c   Harries, Anthony D ^g,k  

^a Pham Ngoc Thach Hospital for Tuberculosis and Lung Disease   (Viet Nam)

^b PASTEUR INSTITUTE   (Viet Nam)

^c BICÊTRE HOSPITAL   (France)

^d ANRS   (Viet Nam)

^e INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^f SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^g INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^h AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j EA4123   (France)

^k LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RIFABUTIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; RITONAVIR; TUBERCULOSTATIC AGENT;

ABDOMINAL MASS; ACUTE HEPATITIS; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CRYPTOCOCCAL MENINGITIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; HEPATITIS; HIV ASSOCIATED TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTERVERTEBRAL DISK HERNIA; LYMPHADENOPATHY; MALE; OPEN STUDY; PNEUMOCYSTIS PNEUMONIA; POLYARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; STEADY STATE; TUBERCULOSIS; VIET NAM; ASIAN CONTINENTAL ANCESTRY GROUP; BIOAVAILABILITY; COMPLICATION; DOSE RESPONSE; DRUG COMBINATION; DRUG-INDUCED LIVER INJURY; ETHNOLOGY; HIV INFECTIONS; TREATMENT OUTCOME;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; RIFABUTIN; RITONAVIR; TREATMENT OUTCOME; TUBERCULOSIS; VIETNAM;

EID: 84899879940     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084866     Document Type: Article

References (34)

1. UNAIDS (2012) Global Report. UNAIDS Report on the Global AIDS Epidemic.
2. World Health Organization (2012) Global Tuberculosis Report. WHO, Geneva Switzerland. WHO/HTM/TB/2012.6.
3. World Health Organization, UNAIDS and UNICEF (2011) Global HIV/AIDS Response. Epidemic update and health sector progress towards Universal Access. Progress Report 2011. WHO, Geneva, Switzerland.
4. UNAIDS and WHO (2012) The Treatment 2.0 Framework for Action: Catalysing the next phase of treatment, care and support.Geneva, Switzerland.
5. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. June 2013. Geneva, Switzerland.
6. Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, et al (2010) The HIV-associated tuberculosis epidemic - when will we act? Lancet 375: 1906-1919.
7. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 365: 1471-1481.
8. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, et al (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365: 1482-1491.
9. Karim SSA, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365: 1492-1501.
10. World Health Organization (2010) Treatment of Tuberculosis. Guidelines. Fourth Edition, 2010. WHO/HTM/TB/2009.420.
11. Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, et al (2012) Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? Int J Tuberc Lung Dis 16: 6-15.
12. Burman W, Gallicano K, Peloquin C (2001) Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials. Clin Pharmacokinet 40: 327-341. (Pubitemid 32565595)
13. Baciewicz AM, Chrisman CR, Finch CK, Self TH (2008) Update on rifampin and rifabutin drug interactions. Am J Med Sci 335: 126-136. (Pubitemid 351253409)
14. Centres for Disease Control & Prevention (1998) Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 47(RR20): 1-51.
15. Centres for Disease Control & Prevention (2004) Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. MMWR 53(RR-15): 1-112.
16. Boulanger C, Hollender E, Farrelll K, Stambaugh JJ, Maasen D, et al (2009) Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 49: 1305-11.
17. Khachi H, O'Connell R, Ladenheim D, Orkin C (2009) Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 64: 871-873.
18. Jenny-Avital E, Joseph K (2009) Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: A report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 48: 1471-1474.
19. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, et al (2005) Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40: 1481-1491. (Pubitemid 40628637)
20. Ministry of Health, Vietnam (2007) Guideline on TB/HIV Control Collaboration. Hanoi, Vietnam.
21. Division of AIDS table for grading the severity of adult and pediatric events (2004) Bethesda, MD: National Institute of Allergy and Infectious Diseases. Available: http://www.niaid.nih.gov/LabsAndResources/resources/ DAIDSClinRsrch/Documents/daidsaegradingtable.pdf. Accessed 2013 May 17.
22. Taburet AM, Raguin AMG, Le Tiec C, Droz C, Barrail A, et al (2004) Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin PharmacolTher 75: 310-323. (Pubitemid 38471556)
23. Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, et al (2011) Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother 66: 2075-2082.
24. Zhang X, Fettner S, Zwanziger E, Rowell L, Salgo M (2011) Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects. Antimicrob Agents Chemother 55: 680-7.
25. Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, et al (2010) Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 54: 4440-5.
26. Ford SL, Chen YC, Lou Y, Borland J, Min SS, et al (2008) Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother 52: 534-8. (Pubitemid 351170825)
27. Naiker S, Connolly C, Weisner L, Phillips D, Harries A, et al (2012) Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on Lopinavir/ritonavir-based antiretroviral therapy. Conference on Retroviruses and Opportunistic Infections, Tuesday, Room 312, Abstract#650.
28. Matteelli A, Villani P, Carvalho AC, El-Hamad I, Cusato M, et al (2012) Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. J Antimicrob Chemother 67: 2470-3.
29. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. Geneva, Switzerland.
30. Lan NTN, Thu NTN, Duc NH, Lan NN, Lien TTX, et al (2013) The ethics of a clinical trial when the protocol clashed with international guidelines. Public Health Action 3: 97-102.
31. Mitchison D, Dickinson JM (1971) Laboratory aspects of intermittent drug therapy. Postgrad med J 47: 737-741.
32. Verbist L (1969) Rifampicin activity "in vitro" and in established mice. Act Tuberc Pneumol Belg 60: 391-408.
33. Jayaram R, Gaoakar S, Kaur P, Surseh BL, Mahesh BN, et al (2003) Pharmacokietcis- pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47: 2118-2124. (Pubitemid 36753560)
34. Gumbo T, Louie A, Dezile MR, Liu W, Parsons LM, et al (2007) Concentration-dependent Mycobacteium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51: 3781-3788. (Pubitemid 350057771)